Cabergoline's Effects on Testosterone and SHBG Levels
Yes, cabergoline significantly increases testosterone levels in men with hyperprolactinemia by normalizing prolactin, but it does not directly affect SHBG levels.
Mechanism and Expected Testosterone Response
Cabergoline restores testosterone primarily by eliminating prolactin-mediated suppression of the hypothalamic-pituitary-gonadal axis. Elevated prolactin inhibits gonadotropin-releasing hormone (GnRH) secretion, which in turn suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to secondary hypogonadism 1. By normalizing prolactin levels, cabergoline removes this inhibitory effect and allows the HPG axis to resume normal function 2.
Testosterone Normalization Timeline
- Testosterone levels begin improving within the first month of cabergoline therapy 3, 4, 5
- 60-73% of men achieve normalized testosterone levels by 6 months of treatment 3, 4, 6
- The magnitude of testosterone increase is substantial: serum testosterone typically rises from subnormal levels (mean 3.7 µg/L) to normal range (mean 5.3 µg/L), with concurrent increases in dihydrotestosterone from 0.4 to 1.1 nmol/L 4
Clinical Outcomes Related to Testosterone Recovery
Sexual function improvements parallel testosterone normalization:
- Libido and erectile function improve in 60-67% of men with prolactinoma treated with cabergoline 2
- Nocturnal penile tumescence normalizes in approximately 61% of patients who achieve prolactin normalization 6
- Sperm parameters (volume, count, motility) normalize in men who achieve testosterone normalization 3, 4
SHBG Considerations
Cabergoline does not directly alter SHBG levels. The 2025 European Association of Urology guidelines list hyperprolactinemia as a cause of secondary hypogonadism but do not identify dopamine agonists as drugs that increase SHBG 1. SHBG levels are primarily influenced by factors such as obesity, insulin resistance, thyroid hormones, and liver disease—not by dopamine agonist therapy 1.
Important Clinical Context
In men with borderline total testosterone but elevated SHBG, measuring free testosterone by equilibrium dialysis is essential to distinguish true hypogonadism from SHBG-related alterations 7. This is particularly relevant when evaluating whether hyperprolactinemia is causing genuine androgen deficiency versus laboratory artifact.
Treatment Response Predictors
Not all men will normalize testosterone despite prolactin normalization:
- Approximately 27-40% of men require continued testosterone or gonadotropin replacement therapy even after successful prolactin normalization 3
- Men with macroprolactinomas and prolonged hyperprolactinemia may have irreversible testicular damage requiring permanent androgen replacement 3, 5
- Younger patients and those with extremely high baseline prolactin levels (markers of larger adenomas) are less likely to achieve complete HPG axis recovery 2
Critical Clinical Pitfall
For men desiring fertility, cabergoline is the preferred treatment over testosterone replacement therapy. While both can improve sexual function, exogenous testosterone suppresses spermatogenesis and causes azoospermia, whereas cabergoline restores endogenous testosterone production and fertility potential 7, 8. Gonadotropin therapy (hCG plus FSH) should be added if fertility is not restored with cabergoline alone 7.
Monitoring Protocol
Testosterone levels should be assessed:
- At baseline (morning levels, 8-10 AM) 7
- Monthly during the first 6 months of cabergoline therapy 3, 4, 5
- Every 3-6 months once prolactin is normalized 8
If testosterone remains low despite normalized prolactin after 6 months, consider: